Leadership Team's Technical Primer Enhances Real-World Evidence (RWE) for Cross-Border Impact, Positioning Fifty1 AI Labs in a $48B Market OpportunityVANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN – Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), announces the publication of a landmark technical primer on "transportability" methods in oncology real-world evidence (RWE). Authored by CTO Alind Gupta and CEO Paul Arora, the primer, published in the Journal of Comparative ...

VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), has entered a groundbreaking partnership with LUNR Aerospace to develop AI-driven drug repurposing initiatives tailored for space medicine. This collaboration targets critical health challenges in microgravity, including immune support, musculoskeletal resilience, neuro-ocular protection (Spaceflight-Associated Neuro-Ocular Syndrome, or SANS), cardiovascular stability, ...

VANCOUVER, British Columbia and PALO ALTO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- via IBN --  Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), together with its commercial partner BioSpark AI Technologies Inc., is announcing a major milestone in its AI-driven drug repurposing and functional medicine initiative. The joint effort has successfully transformed over 10,000 unstructured case reports into a fully structured, queryable database of more than 2,000 real-world patient treatment-outco ...